On May 13th, Gelong Exchange (2096.HK) rose nearly 12% to HK $9.65, a new high in nearly a month, temporarily recording four consecutive increases, with a range of more than 23%, with a total market capitalization of HK $25.5 billion. Shandong Qianfoshan Hospital disclosed last month that Phase I clinical study of oral small molecule candidate drug SIM0417 for 3CL of Xiansheng Pharmaceutical Co., Ltd. has completed the first patient administration, and it is expected that the phase I clinical study of SIM0417 (SSD843) will complete the administration of all subjects by the end of May. It is reported that SIM0417 is an oral small molecule drug candidate for 3CL, a key protease necessary for novel coronavirus replication. As an innovation and R & D-driven pharmaceutical company, the innovative layout of Xiansheng Pharmaceutical Co., Ltd. is not just taking medicine in the popular Xinguan oral medicine. Recently, Xiansheng Pharmaceutical expects to add nearly 10 clinical trial applications (IND) containing both Chinese and American newspapers in 2022 alone.